Citations

Showing 10 of 108083 citations.

Faculty Opinions recommendation of Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.719410596.793538877 Get It

Faculty Opinions recommendation of Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725246158.793538875 Get It

Faculty Opinions recommendation of The histone LSD1 demethylase in stemness and cancer transcription programs.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.719603158.793538873 Get It

Faculty Opinions recommendation of Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718149068.793538876 Get It

Faculty Opinions recommendation of Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 14, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718022169.793538872 Get It

Nomenclature of Cutaneous Vasculitis
Sunderkötter, Cord , Zelger, Bernhard, Chen, Ko‐Ron , Requena, Luis , Piette, Warren W., Dutz, Jan , Lamprecht, Peter , Mahr, Alfred , Aberer, Elisabeth , Wetter, David A. , Kawana, Seiji, Françès, Camille, Jorizzo, Joseph L. , Watts, J. Richard, Metze, Dieter , Caproni, Marzia , Alpsoy, Erkan , Callen, Jeffrey P. , Falk, Ronald J. , Jennette, J. Charles , Mahr, Alfred , Carlson, J. Andrew , Werth, Victoria P. , Luqmani, Raashid Ahmed , Fiorentino, David Franklin , Merkel, Peter A. , Jennette, J Charles , Caproni, Marzia

Mayo Clinic

Arthritis & Rheumatology | November 14, 2017 | Volume: 70 | Issue: 2 | Pages: 171-184

10.1002/art.40375 | PMID 29136340 Get It

Objective To prepare a dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides ( CHCC 2012) to address vasculitides affecting the skin (D‐ CHCC ). The goal was to standardize the names and definitions for cutaneous vasculitis. Methods A nominal group technique with a facilitator was used to reach consensus on the D‐ CHCC nomenclature, using multiple face‐to‐face meetings, e‐mail discussions, and teleconferences. Results Standardized names, definitions, and descriptions were adopted for cutaneous components of systemic vasculitides (e.g., cutaneous IgA vasculitis as a component of systemic IgA vasculitis), skin‐limited variants of systemic vasculitides (e.g., skin‐limited IgA vasculitis, drug‐induced skin‐limited antineutrophil cytoplasmic antibody–associated vasculitis), and cutaneous single‐organ vasculitides that have no systemic counterparts (e.g., nodular vasculitis). Cutaneous vasculitides that were not included in the CHCC 2012 nomenclature were introduced. Conclusion Standardized names and definitions are a prerequisite for developing validated classification and diagnostic criteria for cutaneous vasculitis. Accurate identification of specifically defined variants of systemic and skin‐limited vasculitides requires knowledgeable integration of data from clinical, laboratory, and pathologic studies. This proposed nomenclature of vasculitides affecting the skin, the D‐ CHCC , provides a standard framework both for clinicians and for investigators.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Hendrickson, Andrea E. Wahner , Menefee, Michael E., Hartmann, Lynn C. , Long, Harry J., Northfelt, Donald W. , Boakye‐Agyeman, Felix , Kayode, Olumide, Flatten, Karen S., Harrell, Maria I., Swisher, Elizabeth M. , Poirier, Guy G. , Satele, Daniel , Allred, Jake, Lensing, Janet L., Chen, Alice P. , Ji, Jiuping , Zang, Yiping , Erlichman, Charles , Haluska, Paul , Wahner Hendrickson, Andrea E, Reid, Joel M. , Boakye-Agyeman, Felix, Kaufmann, Scott H. , Swisher, Elizabeth M , Zang, Yiping

Mayo Clinic

Clinical Cancer Research | November 14, 2017 | Volume: 24 | Issue: 4 | Pages: 744-752

10.1158/1078-0432.ccr-17-1590 | PMID 29138343 Get It

Abstract Purpose: To determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative studies were included to assess the impact of topotecan and veliparib on poly(ADP-ribose) levels in peripheral blood mononuclear cells, serum pharmacokinetics of both agents, and potential association of germline repair gene mutations with outcome. Experimental Design: Eligible patients had metastatic nonhematologic malignancies with measurable disease. Using a 3 + 3 design, patients were treated with veliparib orally twice daily on days 1–3, 8–10, and 15–17 and topotecan intravenously on days 2, 9, and 16 every 28 days. Tumor responses were assessed by RECIST. Results: Of 58 patients enrolled, 51 were evaluable for the primary endpoint. The MTD and RP2D was veliparib 300 mg twice daily on days 1–3, 8–10, and 15–17 along with topotecan 3 mg/m2 on days 2, 9, and 16 of a 28-day cycle. DLTs were grade 4 neutropenia lasting >5 days. The median number of cycles was 2 (1–26). The objective response rate was 10%, with 1 complete and 4 partial responses. Twenty-two patients (42%) had stable disease ranging from 4 to 26 cycles. Patients with germline BRCA1, BRCA2, or RAD51D mutations remained on study longer than those without homologous recombination repair (HRR) gene mutations (median 4 vs. 2 cycles). Conclusions: Weekly topotecan in combination with veliparib has a manageable safety profile and appears to warrant further investigation.
Ruxolitinib as first‐line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience
Slostad, Jessica , Hoversten, Patrick , Cisak, Kamila I. , Paludo, Jonas , Tefferi, Ayalew , Cisak, Kamila, Paludo, Jonas , Tefferi, Ayalew , Haddox, Candace L.

Mayo Clinic

American Journal of Hematology | November 14, 2017 | Volume: 93 | Issue: 2 | Pages: No page available

10.1002/ajh.24971 | PMID 29134683 Get It

Update on pulmonary arterial hypertension research: proceedings from a meeting of experts
McLaughlin, Vallerie V. , Bacchetta, Matthew , Badesch, David B., Benza, Raymond L. , Chin, Kelly , Frantz, Robert P. , Frost, Adaani , Rosenzweig, Erika B. , Rubin, Lewis J. , Frantz, Robert, Benza, Raymond L. , Chin, Kelly M , Rosenzweig, Erika B , Frantz, Robert P , McLaughlin, Vallerie V. , Burger, Charles D. , Hemnes, Anna R. , Kim, Nick H.

Mayo Clinic

Current Medical Research and Opinion | November 14, 2017 | Volume: 34 | Issue: 2 | Pages: 263-273

10.1080/03007995.2017.1404974 | PMID 29132217 Get It

Selected Radiation Safety Aspects Including Transportation and Lodging After Outpatient 131 I Therapy for Differentiated Thyroid Cancer
Gomes-Lima, Cristiane , Wu, Di , Kharazi, Pejman, Khojekar, Gauri J., Ringel, Matthew D. , Vetter, Richard J., Bloom, Gary , Burman, Kenneth D. , Wartofsky, Leonard , Nostrand, Douglas Van , Ringel, Matthew D

Mayo Clinic

Thyroid | November 14, 2017 | Volume: 27 | Issue: 12 | Pages: 1558-1565

10.1089/thy.2017.0124 | PMID 29132255 Get It